Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1991 4
1992 5
1993 9
2005 2
2006 1
2007 4
2008 6
2009 5
2010 1
2011 4
2012 2
2013 2
2014 7
2015 9
2016 6
2017 9
2018 11
2019 12
2020 11
2021 12
2022 7
Text availability
Article attribute
Article type
Publication date

Search Results

105 results
Results by year
Filters applied: . Clear all
Page 1
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Armand P, et al. Among authors: de boer jp. J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584546 Free PMC article. Clinical Trial.
Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.
Cioni B, Zaalberg A, van Beijnum JR, Melis MHM, van Burgsteden J, Muraro MJ, Hooijberg E, Peters D, Hofland I, Lubeck Y, de Jong J, Sanders J, Vivié J, van der Poel HG, de Boer JP, Griffioen AW, Zwart W, Bergman AM. Cioni B, et al. Among authors: de boer jp. Nat Commun. 2020 Sep 9;11(1):4498. doi: 10.1038/s41467-020-18313-y. Nat Commun. 2020. PMID: 32908142 Free PMC article.
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, Lubeck Y, Seignette IM, Smit LA, Willems SM, van den Brekel MWM, Dirven R, Baris Karakullukcu M, Karssemakers L, Klop WMC, Lohuis PJFM, Schreuder WH, Smeele LE, van der Velden LA, Bing Tan I, Onderwater S, Jasperse B, Vogel WV, Al-Mamgani A, Keijser A, van der Noort V, Broeks A, Hooijberg E, Peeper DS, Schumacher TN, Blank CU, de Boer JP, Haanen JBAG, Zuur CL. Vos JL, et al. Among authors: de boer jp. Nat Commun. 2021 Dec 22;12(1):7348. doi: 10.1038/s41467-021-26472-9. Nat Commun. 2021. PMID: 34937871 Free PMC article. Clinical Trial.
Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.
de Vries S, Schaapveld M, Janus CPM, Daniëls LA, Petersen EJ, van der Maazen RWM, Zijlstra JM, Beijert M, Nijziel MR, Verschueren KMS, Kremer LCM, van Eggermond AM, Lugtenburg PJ, Krol ADG, Roesink JM, Plattel WJ, van Spronsen DJ, van Imhoff GW, de Boer JP, Aleman BMP, van Leeuwen FE. de Vries S, et al. Among authors: de boer jp. J Natl Cancer Inst. 2021 Jun 1;113(6):760-769. doi: 10.1093/jnci/djaa194. J Natl Cancer Inst. 2021. PMID: 33351090 Free PMC article.
Predicting transformation in follicular lymphoma.
de Jong D, de Boer JP. de Jong D, et al. Among authors: de boer jp. Leuk Lymphoma. 2009 Sep;50(9):1406-11. doi: 10.1080/10428190903093815. Leuk Lymphoma. 2009. PMID: 19606378 Review.
Current treatment options for local residual nasopharyngeal carcinoma.
Stoker SD, van Diessen JN, de Boer JP, Karakullukcu B, Leemans CR, Tan IB. Stoker SD, et al. Among authors: de boer jp. Curr Treat Options Oncol. 2013 Dec;14(4):475-91. doi: 10.1007/s11864-013-0261-5. Curr Treat Options Oncol. 2013. PMID: 24243165 Free PMC article. Review.
Transtympanic Sodium Thiosulfate for Prevention of Cisplatin-Induced Ototoxicity: A Randomized Clinical Trial.
Duinkerken CW, de Weger VA, Dreschler WA, van der Molen L, Pluim D, Rosing H, Nuijen B, Hauptmann M, Beijnen JH, Balm AJM, de Boer JP, Burgers JA, Marchetti S, Schellens JHM, Zuur CL. Duinkerken CW, et al. Among authors: de boer jp. Otol Neurotol. 2021 Jun 1;42(5):678-685. doi: 10.1097/MAO.0000000000003069. Otol Neurotol. 2021. PMID: 33710154 Clinical Trial.
Coagulation disorders in septic shock.
Thijs LG, de Boer JP, de Groot MC, Hack CE. Thijs LG, et al. Among authors: de boer jp. Intensive Care Med. 1993;19 Suppl 1:S8-15. doi: 10.1007/BF01738944. Intensive Care Med. 1993. PMID: 8227738 Review.
EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
Haghiralsadat F, Amoabediny G, Naderinezhad S, Nazmi K, De Boer JP, Zandieh-Doulabi B, Forouzanfar T, Helder MN. Haghiralsadat F, et al. Among authors: de boer jp. Pharm Res. 2017 Dec;34(12):2891-2900. doi: 10.1007/s11095-017-2272-6. Epub 2017 Nov 6. Pharm Res. 2017. PMID: 29110283
105 results